AU2016210068A1 - Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 - Google Patents
Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 Download PDFInfo
- Publication number
- AU2016210068A1 AU2016210068A1 AU2016210068A AU2016210068A AU2016210068A1 AU 2016210068 A1 AU2016210068 A1 AU 2016210068A1 AU 2016210068 A AU2016210068 A AU 2016210068A AU 2016210068 A AU2016210068 A AU 2016210068A AU 2016210068 A1 AU2016210068 A1 AU 2016210068A1
- Authority
- AU
- Australia
- Prior art keywords
- antibodies
- specifically binding
- bispecific
- bispecific antibodies
- antibodies specifically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2022200467A AU2022200467B2 (en) | 2015-01-23 | 2022-01-25 | Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305077.8 | 2015-01-23 | ||
| EP15305077 | 2015-01-23 | ||
| PCT/EP2016/051386 WO2016116626A1 (en) | 2015-01-23 | 2016-01-22 | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022200467A Division AU2022200467B2 (en) | 2015-01-23 | 2022-01-25 | Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016210068A1 true AU2016210068A1 (en) | 2017-09-07 |
| AU2016210068B2 AU2016210068B2 (en) | 2021-10-28 |
Family
ID=52434717
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016210068A Active AU2016210068B2 (en) | 2015-01-23 | 2016-01-22 | Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 |
| AU2022200467A Active AU2022200467B2 (en) | 2015-01-23 | 2022-01-25 | Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022200467A Active AU2022200467B2 (en) | 2015-01-23 | 2022-01-25 | Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US20180057597A1 (en) |
| EP (3) | EP4039710A3 (en) |
| JP (3) | JP6817211B2 (en) |
| KR (2) | KR102680151B1 (en) |
| CN (4) | CN114230668B (en) |
| AR (1) | AR103488A1 (en) |
| AU (2) | AU2016210068B2 (en) |
| BR (1) | BR112017014805A2 (en) |
| CA (2) | CA3251582A1 (en) |
| CL (2) | CL2017001866A1 (en) |
| CO (1) | CO2017008462A2 (en) |
| CR (1) | CR20170383A (en) |
| DO (1) | DOP2017000160A (en) |
| EA (1) | EA201791666A1 (en) |
| EC (1) | ECSP17054182A (en) |
| ES (1) | ES2824167T3 (en) |
| GT (1) | GT201700162A (en) |
| HR (1) | HRP20201517T1 (en) |
| HU (1) | HUE052011T2 (en) |
| IL (2) | IL299975A (en) |
| LT (1) | LT3247725T (en) |
| MA (1) | MA40801B2 (en) |
| MX (3) | MX386535B (en) |
| MY (2) | MY191964A (en) |
| NZ (1) | NZ734803A (en) |
| PE (1) | PE20171764A1 (en) |
| PH (1) | PH12017501190B1 (en) |
| PL (1) | PL3247725T3 (en) |
| PT (1) | PT3247725T (en) |
| RS (1) | RS60916B1 (en) |
| SG (2) | SG10201906762YA (en) |
| SI (1) | SI3247725T1 (en) |
| TN (3) | TN2018000324A1 (en) |
| TW (3) | TW202402802A (en) |
| UA (1) | UA126269C2 (en) |
| UY (1) | UY36536A (en) |
| WO (1) | WO2016116626A1 (en) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI838039B (en) * | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | Dual variable region antibody-like binding proteins having cross-over binding region orientation |
| TN2018000324A1 (en) * | 2015-01-23 | 2020-01-16 | Sanofi Sa | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 |
| EA039859B1 (en) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
| TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for msln and cd3 |
| TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for egfrviii and cd3 |
| TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for flt3 and cd3 |
| BR112018008011A2 (en) | 2015-10-25 | 2018-10-30 | Sanofi | trypecific and / or trivalent binding proteins for prevention or treatment of HIV infection |
| IL260920B (en) | 2016-02-03 | 2022-09-01 | Amgen Res Munich Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs, compositions comprising same and uses thereof |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| KR20240036142A (en) | 2016-04-13 | 2024-03-19 | 사노피 | Trispecific and/or trivalent binding proteins |
| US10882922B2 (en) | 2016-04-13 | 2021-01-05 | Sanofi | Trispecific and/or trivalent binding proteins |
| JP7461741B2 (en) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | Anti-PD-L1 and IL-2 Cytokines |
| TWI790206B (en) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 |
| JP7224289B2 (en) * | 2016-09-21 | 2023-02-17 | アプティーボ リサーチ アンド デベロップメント エルエルシー | CD123 binding proteins and related compositions and methods |
| CN110177809B (en) | 2016-11-16 | 2023-11-03 | 埃博灵克斯股份有限公司 | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta |
| AU2017366739B2 (en) | 2016-12-02 | 2023-11-23 | Angeles Therapeutics, Inc. | Synthetic immune receptors and methods of use thereof |
| FI3561057T3 (en) * | 2016-12-22 | 2025-10-07 | Daiichi Sankyo Co Ltd | Anti-cd3 antibody, and molecule containing said antibody |
| JPWO2018147245A1 (en) * | 2017-02-07 | 2019-11-21 | 第一三共株式会社 | Anti-GPRC5D antibody and molecule containing the antibody |
| CN118562001A (en) * | 2017-05-08 | 2024-08-30 | 阿迪马布有限责任公司 | Anti-CD3 binding domains and antibodies comprising the same and methods of producing and using the same |
| WO2018218207A1 (en) | 2017-05-26 | 2018-11-29 | Fred Hutchinson Cancer Research Center | Anti-cd33 antibodies and uses thereof |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| WO2018237148A1 (en) | 2017-06-21 | 2018-12-27 | Gilead Sciences, Inc. | MULTISPECIFIC ANTIBODIES TARGETING HIV GP120 AND CD3 |
| WO2019018538A1 (en) * | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Recombinant cd123-binding antibodies |
| KR102785140B1 (en) * | 2017-09-21 | 2025-03-25 | 우시 바이올로직스 아일랜드 리미티드 | Novel anti-CD3epsilon antibodies |
| US12486325B2 (en) | 2017-09-21 | 2025-12-02 | WuXi Biologics Ireland Limited | Anti-CD3epsilon antibodies |
| TW201927336A (en) | 2017-10-05 | 2019-07-16 | 日商第一三共股份有限公司 | Composition for depleting cytotoxic T cells |
| SG11202003212PA (en) | 2017-10-10 | 2020-05-28 | Sanofi Sa | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies |
| IL321773A (en) | 2017-10-14 | 2025-08-01 | Cytomx Therapeutics Inc | Activatable antibodies and method for their preparation |
| CA3079788C (en) * | 2017-10-27 | 2023-09-05 | Pfizer Inc. | Antibodies and antibody-drug conjugates specific for cd123 and uses thereof |
| US11067584B2 (en) | 2018-01-12 | 2021-07-20 | Genzyme Corporation | Methods for the quantitation of polypeptides |
| EP3752196A4 (en) * | 2018-02-15 | 2022-03-23 | MacroGenics, Inc. | VARIANT DOMAINS OF CD3 BINDING AND THEIR USE IN MULTITHERAPIES FOR THE TREATMENT OF A DISEASE |
| SMT202500221T1 (en) * | 2018-05-24 | 2025-07-22 | Janssen Biotech Inc | ANTI-CD3 ANTIBODIES AND THEIR USES |
| EP3802617A4 (en) * | 2018-06-07 | 2022-04-27 | Cullinan Oncology, Inc. | MULTI-SPECIFIC BINDING PROTEINS AND METHODS OF USE THEREOF |
| WO2019237350A1 (en) * | 2018-06-15 | 2019-12-19 | 康源博创生物科技(北京)有限公司 | Anti-cd123 antibody and method for preparation thereof and application thereof |
| US12129298B2 (en) | 2018-06-21 | 2024-10-29 | Daiichi Sankyo Company, Limited | Compositions including CD3 antigen binding fragments and uses thereof |
| US20210269525A1 (en) * | 2018-06-29 | 2021-09-02 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | ANTI-CD3e ANTIBODIES AND USES THEREOF |
| EP3849565A4 (en) | 2018-09-12 | 2022-12-28 | Fred Hutchinson Cancer Research Center | REDUCING CD33 EXPRESSION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS |
| BR112021006558A2 (en) | 2018-10-09 | 2021-07-13 | Sanofi | anti-cd38, anti-cd28 and anti-cd3 trispecific binding proteins and methods of use for the treatment of viral infection |
| CN113660944A (en) * | 2018-12-11 | 2021-11-16 | Q32生物公司 | Fusion protein constructs for complement-associated diseases |
| BR112021012338A2 (en) | 2018-12-24 | 2021-09-14 | Sanofi | MULTISPECIFIC BINDING PROTEINS WITH MUTANT FAB DOMAINS |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| MX2021012386A (en) * | 2019-04-09 | 2022-01-18 | Sanofi Sa | Trispecific binding proteins, methods, and uses thereof. |
| KR20230031981A (en) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | Methods and compositions for preventing type 1 diabetes |
| DE102019121007A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigen binding proteins that specifically bind to MAGE-A |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| MX2022002024A (en) * | 2019-08-17 | 2022-03-11 | Igm Biosciences Inc | BIASPECIFIC MULTIMERIC ANTI-CD123 JOINING MOLECULES AND THEIR USES. |
| US12428480B2 (en) | 2019-12-11 | 2025-09-30 | Cullinan Therapeutics, Inc. | Anti-CD19 antibodies and multi-specific binding proteins |
| JP7227895B2 (en) * | 2019-12-23 | 2023-02-22 | 株式会社堀場製作所 | Interaction detection method, interaction detection device, and biochip regeneration kit |
| US20230132241A1 (en) | 2020-01-15 | 2023-04-27 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| CN111171155B (en) * | 2020-02-05 | 2021-02-19 | 北京智仁美博生物科技有限公司 | anti-CD 3 and CD123 bispecific antibodies and uses thereof |
| US20230348571A1 (en) * | 2020-04-06 | 2023-11-02 | Vanderbilt University | Cross-reactive coronavirus antibodies and uses thereof |
| JP2023528350A (en) | 2020-05-27 | 2023-07-04 | ヤンセン バイオテツク，インコーポレーテツド | Protein containing CD3 antigen-binding domain and use thereof |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for preventing type 1 diabetes |
| AU2021357841A1 (en) | 2020-10-08 | 2023-06-15 | Affimed Gmbh | Trispecific binders |
| AU2021414400A1 (en) * | 2020-12-31 | 2023-08-17 | Innate Pharma | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| WO2022150792A1 (en) * | 2021-01-11 | 2022-07-14 | Soteria Biotherapeutics, Inc. | Indinavir based chemical dimerization t cell engager compositions |
| HRP20250696T1 (en) | 2021-01-28 | 2025-08-01 | Regeneron Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR TREATING CYTOKINE RELEASE SYNDROME |
| WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
| JP7708453B2 (en) * | 2021-03-23 | 2025-07-15 | 広州凌騰生物医薬有限公司 | Multispecific antigen-binding proteins that bind to CD3 and methods of use thereof |
| BR112023022765A2 (en) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | ANTIGEN-BINDING PROTEINS THAT SPECIFICALLY BIND PRAME |
| KR20240015093A (en) | 2021-05-27 | 2024-02-02 | 사노피 | Fc variants with improved affinity for Fc receptors and improved thermal stability |
| AU2022320948A1 (en) | 2021-07-30 | 2024-01-18 | Affimed Gmbh | Duplexbodies |
| TW202317639A (en) * | 2021-09-13 | 2023-05-01 | 大陸商江蘇先聲藥業有限公司 | Anti-human CD3 antibody and use thereof |
| EP4416182A4 (en) * | 2021-10-12 | 2025-09-17 | Lepu Biopharma Co Ltd | Anti-CD3 antibodies with cross-reactivity against human and cynomolgus proteins |
| WO2023072217A1 (en) * | 2021-10-28 | 2023-05-04 | Guangzhou Lintonpharm Co., Ltd. | Fusion proteins targeting cd3 and cd47 |
| EP4426439A1 (en) | 2021-11-03 | 2024-09-11 | Affimed GmbH | Bispecific cd16a binders |
| EP4198052A1 (en) | 2021-12-15 | 2023-06-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| TWI849816B (en) * | 2022-03-23 | 2024-07-21 | 大陸商上海濟煜醫藥科技有限公司 | Anti-cd3 antibody, preparation method and application thereof |
| WO2023183600A1 (en) * | 2022-03-25 | 2023-09-28 | Washington University | Systems and methods for monitoring efficacy of cytotoxic treatment |
| PE20250559A1 (en) | 2022-03-29 | 2025-02-24 | Ngm Biopharmaceuticals Inc | ILT3 and CD3 binding agents and methods of using them |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| AU2023274452A1 (en) | 2022-05-27 | 2025-01-16 | Innate Pharma | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| WO2023250434A2 (en) * | 2022-06-22 | 2023-12-28 | The Regents Of The University Of Michigan | Compositions and methods for targeted ides treatment of igg-related disorders |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| AU2023347132A1 (en) * | 2022-09-23 | 2025-04-10 | Guangzhou Lintonpharm Co., Ltd. | Isolated antigen-binding protein and use thereof |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| EP4627096A1 (en) | 2022-12-02 | 2025-10-08 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024173830A2 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
| TW202506727A (en) * | 2023-04-10 | 2025-02-16 | 美商麥迪紐有限責任公司 | Optimized cd3 antigen binding domains |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| WO2024243340A1 (en) | 2023-05-23 | 2024-11-28 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2025109119A1 (en) | 2023-11-22 | 2025-05-30 | Priothera Sas | Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators |
| WO2025131075A1 (en) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | Anti-cd3 and anti-cd3 multispecific antibodies, and use |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025233432A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204A (en) | 1847-07-24 | james cantelo | ||
| US244A (en) | 1837-06-30 | Edward flint | ||
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| JPS63501765A (en) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | Antibody gene module assembly, antibodies produced thereby, and uses |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| WO1991006319A1 (en) | 1989-10-27 | 1991-05-16 | Arch Development Corporation | Methods and compositions for promoting immunopotentiation |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| AU9166691A (en) | 1990-12-20 | 1992-07-22 | Ixsys, Inc. | Optimization of binding proteins |
| DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69434860T2 (en) | 1993-02-22 | 2007-03-15 | The Rockefeller University | PREPARING HELPET-FREE RETROVIRUS HIGH TITANIUM THROUGH TRANSIENTER TRANSFECTION |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| FR2712812B1 (en) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition for the production of therapeutic products in vivo. |
| HU221385B1 (en) | 1994-07-13 | 2002-09-28 | Chugai Pharmaceutical Co Ltd | Reconstituted human antibody against human interleukin-8 |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CN1241944C (en) | 1995-09-11 | 2006-02-15 | 协和发酵工业株式会社 | Antibody againts 'alpha'-chain of human interleukin 5 receptor |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| WO1997024373A1 (en) | 1995-12-29 | 1997-07-10 | Medvet Science Pty. Limited | Monoclonal antibody antagonists to haemopoietic growth factors |
| EP0971952A2 (en) | 1997-04-10 | 2000-01-19 | Royal Netherlands Academy of Arts and Sciences | Diagnosis method and reagents |
| DE19721700C1 (en) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutant OKT3 antibody |
| JP4169478B2 (en) | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | CD19xCD3-specific polypeptide and uses thereof |
| ATE510855T1 (en) | 2000-03-06 | 2011-06-15 | Univ Kentucky Res Found | USE OF AN ANTIBODIES OR AN IMMUNOTOXIN THAT RESPECTIVELY THAT SELECTIVELY BINDS TO CD123 TO IMPAIR HEMATOLOGICAL CANCER PROGENIC CELLS |
| CN1195779C (en) | 2001-05-24 | 2005-04-06 | 中国科学院遗传与发育生物学研究所 | Double-specificity antibody resisting human ovary cancer and human CD3 |
| US20050003403A1 (en) | 2003-04-22 | 2005-01-06 | Rossi Edmund A. | Polyvalent protein complex |
| UA94211C2 (en) * | 2004-06-03 | 2011-04-26 | Новиммюн С.А. | Isolated fully human monoclonal anti-cd3 antibody |
| EA010350B1 (en) | 2004-06-03 | 2008-08-29 | Новиммун С.А. | Anti-cd3 antibodies and methods of use thereof |
| KR101363120B1 (en) * | 2005-02-10 | 2014-02-13 | 베일러 리서치 인스티튜트 | Anti-Interferon Alpha Monoclonal Antibodies and Methods for Use |
| HUE040467T2 (en) | 2007-04-03 | 2019-03-28 | Amgen Res Munich Gmbh | Cross-species-specific binding domain |
| FI2155783T4 (en) * | 2007-04-03 | 2022-12-15 | Cross-species-specific cd3-epsilon binding domain | |
| HUE037489T2 (en) | 2007-08-29 | 2018-08-28 | Sanofi Sa | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| WO2010037836A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific psmaxcd3 bispecific single chain antibody |
| PL2426148T3 (en) | 2009-04-27 | 2016-01-29 | Kyowa Hakko Kirin Co Ltd | Anti-il-3ra antibody for use in treatment of blood tumor |
| CA2789810C (en) | 2010-02-17 | 2020-12-01 | Csl Limited | Compositions and methods for targeting type 1 interferon-producing cells |
| WO2011109588A1 (en) * | 2010-03-03 | 2011-09-09 | Health Research Inc. | Novel cd3 epsilon immunogens and antibodies |
| WO2011156860A1 (en) * | 2010-06-15 | 2011-12-22 | Csl Limited | IMMUNOTHERAPEUTIC METHOD INVOLVING CD123 (IL-3Rα) ANTIBODIES AND IMMUNOSTIMULATING COMPLEX |
| NZ604510A (en) * | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| TWI838039B (en) * | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | Dual variable region antibody-like binding proteins having cross-over binding region orientation |
| SG195072A1 (en) | 2011-05-21 | 2013-12-30 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
| CN102796199A (en) * | 2011-05-26 | 2012-11-28 | 中国医学科学院血液病医院 | Fusion protein mutant of anti-cluster of differetiation (CD3) antibody Fv segment and interleukin 3, method for preparing fusion protein mutant and application of fusion protein mutant |
| CN102796198A (en) | 2011-05-26 | 2012-11-28 | 中国医学科学院血液病医院 | Fusion protein of anti-cluster of differetiation (CD3) antibody Fv segment and interleukin 3, method for preparing fusion protein and application of fusion protein |
| CN104379601B (en) | 2012-02-03 | 2021-04-09 | 霍夫曼-拉罗奇有限公司 | Bispecific antibody molecules and antigen-transfected T-cells and their use in medicine |
| MX366813B (en) | 2012-04-20 | 2019-07-25 | Aptevo Res & Development Llc | Cd3 binding polypeptides. |
| EP4053162A1 (en) | 2012-05-18 | 2022-09-07 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
| MX2015008446A (en) | 2012-12-28 | 2016-10-26 | Abbvie Inc | Multivalent binding protein compositions. |
| JP2016093104A (en) * | 2013-02-19 | 2016-05-26 | 国立大学法人京都大学 | Anti-human CD3ε antibody or fragment thereof, and immunosuppressant comprising the same as an active ingredient |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| RU2708314C2 (en) * | 2013-03-11 | 2019-12-05 | Джензим Корпорейшн | Hyperglycosylated binding polypeptides |
| US9683039B2 (en) * | 2013-03-14 | 2017-06-20 | New York University | Notch agonists for the treatment of cancer |
| WO2014138819A1 (en) | 2013-03-14 | 2014-09-18 | Csl Limited | Agents that neutralize il-3 signaling and uses thereof |
| US20160031996A1 (en) * | 2013-03-14 | 2016-02-04 | Csl Limited | Anti il-3r alpha agents and uses thereof |
| CA2903258C (en) | 2013-03-15 | 2019-11-26 | Amgen Inc. | Heterodimeric bispecific antibodies |
| AR095374A1 (en) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | UNION MOLECULES FOR BCMA AND CD3 |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| SG11201509361TA (en) * | 2013-05-28 | 2015-12-30 | Numab Ag | Novel antibodies |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| JO3568B1 (en) | 2014-09-05 | 2020-07-05 | Janssen Pharmaceutica Nv | CD123 binding agents and their uses |
| TN2018000324A1 (en) * | 2015-01-23 | 2020-01-16 | Sanofi Sa | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 |
| EA036156B1 (en) | 2015-05-08 | 2020-10-07 | Ксенкор, Инк. | Heterodimeric antibodies that bind cd3 and tumor antigens |
| US10882922B2 (en) * | 2016-04-13 | 2021-01-05 | Sanofi | Trispecific and/or trivalent binding proteins |
| TWI790206B (en) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 |
| SG11202003212PA (en) * | 2017-10-10 | 2020-05-28 | Sanofi Sa | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies |
| BR112021006558A2 (en) * | 2018-10-09 | 2021-07-13 | Sanofi | anti-cd38, anti-cd28 and anti-cd3 trispecific binding proteins and methods of use for the treatment of viral infection |
-
2016
- 2016-01-22 TN TNP/2018/000324A patent/TN2018000324A1/en unknown
- 2016-01-22 WO PCT/EP2016/051386 patent/WO2016116626A1/en not_active Ceased
- 2016-01-22 TN TNP/2018/000325A patent/TN2018000325A1/en unknown
- 2016-01-22 PL PL16701353T patent/PL3247725T3/en unknown
- 2016-01-22 PH PH1/2017/501190A patent/PH12017501190B1/en unknown
- 2016-01-22 HU HUE16701353A patent/HUE052011T2/en unknown
- 2016-01-22 CN CN202111365671.4A patent/CN114230668B/en active Active
- 2016-01-22 CN CN202111365516.2A patent/CN114230667A/en active Pending
- 2016-01-22 UA UAA201708583A patent/UA126269C2/en unknown
- 2016-01-22 MY MYPI2017702398A patent/MY191964A/en unknown
- 2016-01-22 NZ NZ734803A patent/NZ734803A/en unknown
- 2016-01-22 MY MYPI2021000632A patent/MY202412A/en unknown
- 2016-01-22 TW TW112134826A patent/TW202402802A/en unknown
- 2016-01-22 BR BR112017014805-6A patent/BR112017014805A2/en active Search and Examination
- 2016-01-22 EA EA201791666A patent/EA201791666A1/en unknown
- 2016-01-22 PT PT167013531T patent/PT3247725T/en unknown
- 2016-01-22 JP JP2017538599A patent/JP6817211B2/en active Active
- 2016-01-22 AR ARP160100178A patent/AR103488A1/en unknown
- 2016-01-22 EP EP22152787.2A patent/EP4039710A3/en active Pending
- 2016-01-22 SG SG10201906762YA patent/SG10201906762YA/en unknown
- 2016-01-22 CR CR20170383A patent/CR20170383A/en unknown
- 2016-01-22 MX MX2017009535A patent/MX386535B/en unknown
- 2016-01-22 KR KR1020177023344A patent/KR102680151B1/en active Active
- 2016-01-22 MA MA40801A patent/MA40801B2/en unknown
- 2016-01-22 IL IL299975A patent/IL299975A/en unknown
- 2016-01-22 CA CA3251582A patent/CA3251582A1/en active Pending
- 2016-01-22 ES ES16701353T patent/ES2824167T3/en active Active
- 2016-01-22 SG SG11201705925PA patent/SG11201705925PA/en unknown
- 2016-01-22 TW TW110113349A patent/TW202130662A/en unknown
- 2016-01-22 AU AU2016210068A patent/AU2016210068B2/en active Active
- 2016-01-22 EP EP16701353.1A patent/EP3247725B1/en active Active
- 2016-01-22 SI SI201630932T patent/SI3247725T1/en unknown
- 2016-01-22 PE PE2017001243A patent/PE20171764A1/en unknown
- 2016-01-22 HR HRP20201517TT patent/HRP20201517T1/en unknown
- 2016-01-22 CN CN202510832113.6A patent/CN120988137A/en active Pending
- 2016-01-22 CA CA2974453A patent/CA2974453A1/en active Pending
- 2016-01-22 CN CN201680017477.8A patent/CN107428835B/en active Active
- 2016-01-22 LT LTEP16701353.1T patent/LT3247725T/en unknown
- 2016-01-22 TN TN2017000275A patent/TN2017000275A1/en unknown
- 2016-01-22 RS RS20201167A patent/RS60916B1/en unknown
- 2016-01-22 KR KR1020247021409A patent/KR20240104220A/en active Pending
- 2016-01-22 TW TW105102149A patent/TWI726862B/en active
- 2016-01-22 EP EP20170198.4A patent/EP3812398A3/en not_active Withdrawn
- 2016-01-25 UY UY0001036536A patent/UY36536A/en not_active Application Discontinuation
-
2017
- 2017-07-04 DO DO2017000160A patent/DOP2017000160A/en unknown
- 2017-07-19 IL IL253569A patent/IL253569B2/en unknown
- 2017-07-19 CL CL2017001866A patent/CL2017001866A1/en unknown
- 2017-07-20 US US15/654,857 patent/US20180057597A1/en not_active Abandoned
- 2017-07-20 GT GT201700162A patent/GT201700162A/en unknown
- 2017-07-21 MX MX2021011696A patent/MX2021011696A/en unknown
- 2017-07-21 MX MX2021011697A patent/MX2021011697A/en unknown
- 2017-08-21 EC ECIEPI201754182A patent/ECSP17054182A/en unknown
- 2017-08-22 CO CONC2017/0008462A patent/CO2017008462A2/en unknown
-
2018
- 2018-04-02 US US15/943,685 patent/US10906978B2/en active Active
- 2018-08-31 CL CL2018002490A patent/CL2018002490A1/en unknown
-
2020
- 2020-12-23 JP JP2020213051A patent/JP7269215B2/en active Active
-
2021
- 2021-01-12 US US17/147,255 patent/US20210292423A1/en active Pending
-
2022
- 2022-01-25 AU AU2022200467A patent/AU2022200467B2/en active Active
-
2023
- 2023-04-20 JP JP2023068919A patent/JP7692448B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3251582A1 (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
| AU2016210068A1 (en) | Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 | |
| ZA202203250B (en) | Cd3 binding antibodies | |
| ZA202006983B (en) | Bispecific antibody constructs binding dll3 and cd3 | |
| IL263840A (en) | Cd3 binding antibodies | |
| IL256870A (en) | Constructs for bispecific antibodies binding cd70 and cd3 and uses thereof | |
| IL264248A (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| IL256872A (en) | Constructs for bispecific antibodies binding egfrviii and cd3 and uses thereof | |
| IL256873A (en) | Constructs for bispecific antibodies binding mesothelin and cd3 and uses thereof | |
| IL258036A (en) | Optimized anti-cd3 bispecific antibodies and uses thereof | |
| HK1239720B (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
| HK1239720A1 (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
| HK40001468A (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| HK40006209A (en) | Cd3 binding antibodies | |
| HK40010072A (en) | Cd3 binding antibodies |